Growth hormone is naturally hormone secreted by pituitary gland of human body. It regulated various complex physiological process of the body which mainly includes growth and metabolism. It plays a role in achieving normal growth in children and is also help to regulate lipid, carbohydrate, and protein metabolism in all age groups (childhood & adulthood). The synthetic form of human growth hormone is known as somatropin. Until 1985, the growth hormone is obtained through extraction from cadaveric pituitary glands due to its side effect it was discontinued and the first synthetic growth hormone was approved by the U.S. Food Drug Administration in 1985 for the treatment of growth hormone deficiency. It is also approved for the treatment of chronic renal insufficiency, adult growth hormone deficiency, truners syndrome, prader-willi syndrome, idiopathic short stature and Noona syndrome. It is also as anti-aging therapy yet is not approved for this indication. Many synthetic human growth hormone is now available in the market which include Humatrope (Lilly), Nutropin (Genentech), Norditropin (Novo), Genotropin (Pfizer), and Saizen (Merck Serono). As of 2006, the recombinant version of somatroin was lauched a ‘Omnitrope’ by Sandoz. Growing demand for somatropin, led by rising growth hormone deficiency cases and advancement in rDNA technology have boosted the growth of global somatropin market in forecast period. Moreover, ongoing clinical trials of somatropin in various therapeutic areas further drive the growth of the market. However, stringent regulatory process and complicated manufacturing process are the factors restrain the growth of the global somatropin market.
Request For Sample @ https://bit.ly/2HcM439
The global somatropin market is segmented on the basis of application, distribution channel and geography. On the basis of application the global somatropin market is further sub-segmented into chronic renal insufficiency, growth hormone deficiency, turners syndrome, prader-willi syndrome, idiopathic short stature and Noona syndrome. Growth hormone deficiency followed turners syndrome segment is expected to hold the significant share of the market due to increase in number of patients suffering from pitutary dysfunction, and effectivity of the somatropin to treat turners syndrome. Based on distribution channel the global somatropin market is segmented into online pharmacy, hospital pharmacy and retail pharmacy. Hospital pharmacy is major contributor in terms of revenue to the market as somatropin available on prescription and increase number of hospital visits.
Request For Table Of Content (TOC) @ https://bit.ly/2HcM439
At regional level, the global Somatropin market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, North America followed by Europe is major contributor for the global somatropin market. This is partly because of increased government initiatives for cost effective treatment and rising number of pituitary dysfunction cases. Furthermore, strong clinical pipeline and increasing research and drug development activities propels the growth of the market in these regions. Asia Pacific is third promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors for this market and are identified as most lucrative for this market. Emerging and huge population base countries such as China and India offers tremendous market opportunities.
Some of the market players leading the global somatropin market include Sandoz, F. Hoffmann-La Roche AG, Pfizer, Eli Lilly and Company, Novo Nordisk, Merck co. and many more
Know More About [email protected]